17-08-2016 | Cardiometabolic | News | Article
PCSK9 inhibitors not cost-effective at current prices
Proprotein convertase subtilisin/kexin type 9 inhibitors are not currently cost effective for the prevention of cardiovascular events in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, US research shows.
05-08-2016 | Diabetes | News | Article
Low diabetes risk from medium-term PCSK9 inhibition
Pooled data from the ODYSSEY phase III trials show that PCSK9 inhibition does not result in excess cases of new-onset diabetes during up to 18 months of treatment, despite mounting evidence that lowering cholesterol levels increases diabetes risk.
02-08-2016 | Cardiometabolic | News | Article
Statin benefits dependent on baseline kidney function
The benefits of statin-based treatments among patients with chronic kidney disease diminish with decreasing estimated glomerular filtration rate, with little evidence of any benefit for patients on dialysis, results of a large meta-analysis show.
21-04-2013 | Metabolism | Article
Orlistat liver injury link questioned
Researchers have found that users of the obesity drug, orlistat, have an increased risk for acute liver injury compared with non-users in the time period prior to taking the drug.
Salmon_avocado_nuts/© Yulia Furman / Fotolia, Pills_various/© nikesidoroff / fotolia.com, pills, Statin tablets/© roger ashford / fotolia.com, Cholesterol_test results/© jarun011 / fotolia.com